• Restore CFTR FunctionCompleted with Results

  Phase 3 study of VX-659 triple combination drug in people with CF ages 12 years and older who have two copies of the F508del mutation , protocol number VX17-659-103

  This study evaluated the safety and effectiveness of the drug VX-659 in combination with tezacaftor and ivacaftor in people with cystic fibrosis ages 12 and older with two copies of the F508del CFTR mutation.

  • Age:

    12 Years and Older

  • Mutation(s):

    Two Copies F508del

  • FEV1% Predicted:

    40 to 90%

  • Number of Visits:

    7

  • Length of Participation:

    10 weeks

• Restore CFTR FunctionCompleted with Results

  Phase 3 study of VX-659 triple combination drug in people with CF 12 years and older who have one copy of the F508del mutation and one copy of a minimal function mutation , protocol number VX17-659-102

  This study evaluated the safety and effectiveness of the drug VX-659 in combination with tezacaftor and ivacaftor in people with cystic fibrosis ages 12 and older with one copy of the F508del CFTR mutation and one copy of a minimal function mutation.

  • Age:

    12 Years and Older

  • Mutation(s):

    One Copy F508del

  • FEV1% Predicted:

    40 to 90%

  • Number of Visits:

    10

  • Length of Participation:

    32 weeks

• Restore CFTR FunctionCompleted with Results

  Phase 2 study of VX-659 combination drug in adults with cystic fibrosis , protocol number Vertex VX16-659-101

  This study evaluated the safety, tolerability and effectiveness of the drug VX-659 in combination with tezacaftor/ivacaftor (Symdeko®) in people who either have two copies of the F508del CFTR mutation or have one copy of F508del and one copy of a minimal function CFTR mutation.

  • Age:

    18 Years and Older

  • Mutation(s):

    Two Copies F508del or One Copy F508del

  • FEV1% Predicted:

    40% or greater

  • Number of Visits:

    6

  • Length of Participation:

    8 weeks

Studies in this tool are multi-center studies facilitated by the Cystic Fibrosis Therapeutics Development Network. For a complete list of cystic fibrosis related studies, visit www.clinicaltrials.gov.